Daniel Stover

Daniel Stover, MD


Overall Patient Satisfaction Rating

4.9 out of 5




I am a medical oncologist specializing in the treatment of breast cancer and a scientist focusing on improving the understanding and treatment of breast cancer. I attended medical school and completed my residency at the Vanderbilt University School of Medicine. I completed my medical oncology and research fellowships at the Dana-Farber Cancer Institute and Harvard Medical School in Boston, Massachusetts. In addition to my work at the OSUCCC – James, I also serve as an assistant professor in Internal Medicine at The Ohio State University.

My research focuses on integrating tumor genomic profiling with patient characteristics and outcomes with a goal to develop new treatments for breast cancer. My work has been published in numerous journals, including Nature, Cell, Nature Medicine, Journal of Clinical Oncology, and Clinical Cancer Research among others.

My first exposure to oncology occurred as a high schooler in a cancer research lab at the OSUCCC – James. In 2017, I returned to The James as a faculty member after 18 years of diverse training across the country. At The James, our dedication to patient care is unmatched, and I’m honored to be part of a center that looks at every aspect of a patient’s treatment, from diagnosis to management. I’m confident our work, research and collaboration will move us closer to a cancer-free world.

Education and Background


Vanderbilt University School of Medicine

Nashville, TN


Vanderbilt University Medical Center

Nashville, TN


Medical Oncology

Dana Farber Cancer Institute

Boston, MA

Board Certifications

American Board of Internal Medicine

American Board of Internal Medicine

American Board of Internal Medicine (Subspecialty: Medicine Oncology)

American Board of Internal Medicine (Subspecialty: Medicine Oncology)

Academic Department

Department of Internal Medicine

Division of Medical Oncology

Consulting and Related Relationships

At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 11/21/2019, Dr. Stover has reported no relationships with companies or entities.


Patient Satisfaction Review

The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our Patient Satisfaction Survey page

The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.

Overall Ratings (out of 40 reviews)
4.9 out of 5
Kept you informed about your condition and treatment

4.9/ 5

Amount of time spent with you

4.9/ 5

Concern for your questions and issues

4.9/ 5

Skill and knowledge

4.9/ 5

Overall quality of care

4.9/ 5

Patient Comments (3 total comments)

Reviewed: 11/5/2019


Reviewed: 9/30/2019

Dr. Stover is always patient and makes time for questions.

Reviewed: 2/22/2019

I was extremely impressed with Dr. Stover, the simple language he used to help me understand the situation and his opinion.


Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies.

Jiang YZ, Ma D, Suo C, Shi J, Xue M, Hu X, Xiao Y, Yu KD, Liu YR, Yu Y, Zheng Y, Li X, Zhang C, Hu P, Zhang J, Hua Q, Zhang J, Hou W, Ren L, Bao D, Li B, Yang J, Yao L, Zuo WJ, Zhao S, Gong Y, Ren YX, Zhao YX, Yang YS, Niu Z, Cao ZG, Stover DG, Verschraegen C, Kaklamani V, Daemen A, Benson JR, Takabe K, Bai F, Li DQ, Wang P, Shi L, Huang W, Shao ZM

Cancer Cell 35


Correction: ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors.

Guerrero-Zotano AL, Stricker TP, Formisano L, Hutchinson KE, Stover DG, Lee KM, Schwarz LJ, Giltnane JM, Estrada MV, Jansen VM, Servetto A, Gavilá J, Perez-Fidalgo JA, Lluch A, Llombart-Cussac A, Bayar MA, Michiels S, André F, Arnedos M, Guillem V, Ruiz-Simon A, Arteaga CL

Clin Cancer Res 25


Back to Find a Doctor Search

Make an Appointment


Please enter a keyword (i.e. Name, Cancer Type) or choose a Principle Investigator


Please enter a keyword (i.e. Name, Location) or choose a Cancer Type